CN116492412B - 一种治疗血虚络阻证末梢神经炎的中药组合物 - Google Patents
一种治疗血虚络阻证末梢神经炎的中药组合物 Download PDFInfo
- Publication number
- CN116492412B CN116492412B CN202310414806.4A CN202310414806A CN116492412B CN 116492412 B CN116492412 B CN 116492412B CN 202310414806 A CN202310414806 A CN 202310414806A CN 116492412 B CN116492412 B CN 116492412B
- Authority
- CN
- China
- Prior art keywords
- blood
- parts
- root
- pain
- numbness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008280 blood Substances 0.000 title claims abstract description 169
- 210000004369 blood Anatomy 0.000 title claims abstract description 168
- 239000003814 drug Substances 0.000 title claims abstract description 164
- 206010029240 Neuritis Diseases 0.000 title claims abstract description 70
- 201000001119 neuropathy Diseases 0.000 title claims abstract description 67
- 230000007812 deficiency Effects 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 208000011580 syndromic disease Diseases 0.000 title claims description 36
- 241000405414 Rehmannia Species 0.000 claims abstract description 19
- 241001522129 Pinellia Species 0.000 claims abstract description 15
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 13
- 241000501743 Gentiana macrophylla Species 0.000 claims abstract description 13
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 12
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 11
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 11
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 241000202726 Bupleurum Species 0.000 claims abstract description 6
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000011248 coating agent Substances 0.000 claims description 37
- 238000000576 coating method Methods 0.000 claims description 37
- 239000000843 powder Substances 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 244000236658 Paeonia lactiflora Species 0.000 claims description 10
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 10
- 235000012907 honey Nutrition 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 239000007779 soft material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000009495 sugar coating Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 241000112528 Ligusticum striatum Species 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 241000736199 Paeonia Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 99
- 208000024891 symptom Diseases 0.000 abstract description 99
- 230000000694 effects Effects 0.000 abstract description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 41
- 201000010099 disease Diseases 0.000 abstract description 39
- 229940079593 drug Drugs 0.000 abstract description 30
- 230000017531 blood circulation Effects 0.000 abstract description 23
- 230000001737 promoting effect Effects 0.000 abstract description 21
- 230000003213 activating effect Effects 0.000 abstract description 18
- 241000007126 Codonopsis pilosula Species 0.000 abstract description 9
- 208000005392 Spasm Diseases 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 7
- 230000001174 ascending effect Effects 0.000 abstract description 6
- 241000756943 Codonopsis Species 0.000 abstract description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract description 4
- 235000021419 vinegar Nutrition 0.000 abstract description 4
- 239000000052 vinegar Substances 0.000 abstract description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 241000721047 Danaus plexippus Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 208000034783 hypoesthesia Diseases 0.000 description 130
- 208000004044 Hypesthesia Diseases 0.000 description 117
- 231100000862 numbness Toxicity 0.000 description 114
- 238000011282 treatment Methods 0.000 description 100
- 210000003414 extremity Anatomy 0.000 description 62
- 210000002683 foot Anatomy 0.000 description 60
- 238000003745 diagnosis Methods 0.000 description 55
- 206010061876 Obstruction Diseases 0.000 description 39
- 210000003141 lower extremity Anatomy 0.000 description 38
- 210000004247 hand Anatomy 0.000 description 37
- 210000003205 muscle Anatomy 0.000 description 27
- 208000006820 Arthralgia Diseases 0.000 description 26
- 210000002435 tendon Anatomy 0.000 description 20
- 210000003371 toe Anatomy 0.000 description 20
- 201000000585 muscular atrophy Diseases 0.000 description 17
- 208000035824 paresthesia Diseases 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 238000001467 acupuncture Methods 0.000 description 15
- 230000001976 improved effect Effects 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 230000001717 pathogenic effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 210000004243 sweat Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 210000001364 upper extremity Anatomy 0.000 description 11
- 206010063659 Aversion Diseases 0.000 description 10
- 229920000742 Cotton Polymers 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 10
- 206010037660 Pyrexia Diseases 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 239000002398 materia medica Substances 0.000 description 10
- 208000026435 phlegm Diseases 0.000 description 10
- 230000007958 sleep Effects 0.000 description 10
- 208000003251 Pruritus Diseases 0.000 description 9
- 240000007164 Salvia officinalis Species 0.000 description 9
- 206010042674 Swelling Diseases 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 208000002173 dizziness Diseases 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 235000005412 red sage Nutrition 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000035807 sensation Effects 0.000 description 9
- 235000019615 sensations Nutrition 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 230000035922 thirst Effects 0.000 description 9
- 241000212322 Levisticum officinale Species 0.000 description 8
- 206010033799 Paralysis Diseases 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 230000007803 itching Effects 0.000 description 8
- 239000001645 levisticum officinale Substances 0.000 description 8
- 230000027939 micturition Effects 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 230000011514 reflex Effects 0.000 description 8
- 238000005728 strengthening Methods 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 241000510654 Bupleurum chinense Species 0.000 description 7
- 240000004371 Panax ginseng Species 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 208000004998 Abdominal Pain Diseases 0.000 description 6
- 206010013954 Dysphoria Diseases 0.000 description 6
- 206010049816 Muscle tightness Diseases 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 238000002567 electromyography Methods 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000003127 knee Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010006784 Burning sensation Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 229960005321 mecobalamin Drugs 0.000 description 5
- 235000007672 methylcobalamin Nutrition 0.000 description 5
- 239000011585 methylcobalamin Substances 0.000 description 5
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 238000000554 physical therapy Methods 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010024642 Listless Diseases 0.000 description 4
- 208000010428 Muscle Weakness Diseases 0.000 description 4
- 206010028372 Muscular weakness Diseases 0.000 description 4
- 206010036105 Polyneuropathy Diseases 0.000 description 4
- 206010062519 Poor quality sleep Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000009194 climbing Effects 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 208000017971 listlessness Diseases 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- 208000019629 polyneuritis Diseases 0.000 description 4
- 230000002040 relaxant effect Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 229940126673 western medicines Drugs 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- 210000000707 wrist Anatomy 0.000 description 4
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 241000219780 Pueraria Species 0.000 description 3
- 208000020764 Sensation disease Diseases 0.000 description 3
- 206010040925 Skin striae Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 229960000623 carbamazepine Drugs 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 208000023652 chronic gastritis Diseases 0.000 description 3
- 238000007596 consolidation process Methods 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000001513 elbow Anatomy 0.000 description 3
- 210000002310 elbow joint Anatomy 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 238000003958 fumigation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 3
- 208000003906 hydrocephalus Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 230000001314 paroxysmal effect Effects 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 229960004380 tramadol Drugs 0.000 description 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 208000001034 Frostbite Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 241000256602 Isoptera Species 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010040026 Sensory disturbance Diseases 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000000467 autonomic pathway Anatomy 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 2
- 229960001625 furazolidone Drugs 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000011229 interlayer Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000027905 limb weakness Diseases 0.000 description 2
- 231100000861 limb weakness Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000003582 temporal bone Anatomy 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001633583 Adenophora Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002515 Animal bite Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 206010008428 Chemical poisoning Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- -1 DIBAWA Substances 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010050256 Dysstasia Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023201 Joint contracture Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241001227561 Valgus Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 201000011666 conjunctival pterygium Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Natural products CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960001604 ferrous succinate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000010409 ironing Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000004446 light reflex Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NNKVPIKMPCQWCG-UHFFFAOYSA-N methamidophos Chemical compound COP(N)(=O)SC NNKVPIKMPCQWCG-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 210000002320 radius Anatomy 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000021670 response to stimulus Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000036413 temperature sense Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种治疗血虚络阻证末梢神经炎的中药组合物,包括醋北柴胡、秦艽、清半夏、党参、桂枝、炒白芍、葛根、川芎、熟地黄、当归、丹参和炙甘草。选用纯天然中药原材料,方以当归补血活血通络,党参补中益气养血,两药合用益气养血为君;白芍养血通络,熟地黄滋阴补血,川芎行气活血止痛,丹参活血祛瘀,通经止痛,以上四药活血补血通络止痛为臣;秦艽、清半夏、桂枝、葛根四药升阳活血通经共为佐;醋北柴胡升阳和解表里,炙甘草益气、缓急止痛、调和诸药为使。以上诸药合用,既能活血祛瘀通络,又能益气养血,攻补兼施,标本兼治,对于血虚络阻证末梢神经炎疗效显著,使用安全方便。
Description
技术领域
本发明属于中医药领域,具体涉及一种治疗血虚络阻证末梢神经炎的中药组合物。
背景技术
末梢神经炎也称多发性神经炎、周围神经炎,是各种病因引起的肢体远端神经功能障碍。临床表现主要有肢体远端对称性感觉、运动和自主神经功能异常。症状多表现为受累肢体远端呈手套短袜型感觉减退、麻木或针刺、蚁走、烧灼、触痛和感觉过敏等刺激性症状,甚则肌肉萎缩。针对病因进行治疗,可减轻症状恢复受损神经,对病因不明或原发病难治的多发性神经炎则疗效不佳。研究表明,末梢神经炎总体患病率约为1%,其在老年人群中上升至7%,且有迹象表明女性比男性更易受影响。末梢神经炎发病的病因及具体发病机制目前尚无明确定论,现代医学认为引起本病的病因主要包括中毒、感染、自身免疫疾病、变态反应、代谢及营养障碍等。其病理改变主要是周围神经轴突变性、神经元变性、节段性脱髓鞘病变,自远端逐渐向近端发展为逆死性神经病。因末梢神经炎致病原因不明,且个体差异较大,西医以营养神经、改善微循环、缓解疼痛等药物对症治疗为主,其临床疗效不甚理想,特别是对于有顽固性麻木症状的患者,效果甚微。
祖国医学虽然没有关于“末梢神经炎”的记载,根据其症状、病况转归可属于中医记载的“痹证”范畴,基本病机是气血不足,脉络痹阻。本病的发生多由于各种疾病如消渴、淋病,或外感邪气,久病耗伤气血,或年老体弱,营卫气血不足,不能濡养肌肤;气虚不能推动血行,血行瘀滞;气血不足,卫外不固,感受外邪,经脉痹阻。手得血能握,足得血能步,气血不足,肢体失养则会出现麻木,四肢无力;湿浊痰瘀阻络,血行瘀滞,不通则痛,感觉异常,行走不能,甚至出现肌肉萎缩之症。现代医家将末梢神经炎分为气虚寒湿证、气虚湿热证、瘀血寒湿证、瘀血湿热证、气滞血瘀证、阳虚痰热证。目前研究对于血虚络阻的报道不多,末梢神经炎血瘀络阻证中医病因病机可概括为肝肾、脾胃功能受损,导致机体气血功能障碍,病久气虚运血无力,渐致瘀血内停、血行瘀滞而引起,临床表现中血虚则四肢失养,故见肢体关节肌肉酸痛、麻木,肌肉萎缩,隐隐疼痛;血虚脉络空虚,组织失养则面色萎黄或淡白无华,口唇、爪甲色淡,脉细无力;血虚脏器失养则头晕眼花、神疲乏力。瘀阻则见肢体、关节、肌肉,则肢体沉重、酸困;肢体舌淡,苔薄白,脉弦细或细涩均为血虚瘀阻之象。血虚络阻证的末梢神经炎,症见:肢体局部麻木疼痛,恶风怕冷,肢体抬举无力,病久或见肌肉萎缩,舌质淡白,苔薄白,脉沉细。
发明内容
鉴于上述现有技术,本发明提供一种治疗血虚络阻证末梢神经炎的中药组合物。
本发明的目的是以下述方式实现的:
一种治疗血虚络阻证末梢神经炎的中药组合物,包括以下重量份的各原料,醋北柴胡12-18份,秦艽12-18份,清半夏6-12份,党参14-26份,桂枝12-18份,炒白芍14-26份,葛根14-26份,川芎9-15份,熟地黄14-26份,当归12-18份,丹参21-39份),炙甘草7-13份。
一种治疗血虚络阻证末梢神经炎的中药组合物,包括以下重量份的各原料,醋北柴胡15份,秦艽15份,清半夏9份,党参20份,桂枝15份,炒白芍20份,葛根20份,川芎12份,熟地黄20份,当归15份,丹参30份,炙甘草10份。
所述中药组合物剂型为汤剂、丸剂、片剂、胶囊剂、膏滋、糊剂、散剂。
中药组合物的丸剂制备方法,包括以下步骤,
(1)按照重量份称取各原料药;
(2)将上述各中药原料用粉碎机粉碎成细粉,然后置于混合机中混合均匀,即得粉料;
(3)取100份上述制备得到的粉料置于混合机中,先加入淀粉和蜂蜜搅拌混合15min,再加入纯水搅拌30min,得到软材;
(4)将上述软材置于自动制丸机中拉条、搓丸,得圆整均匀、外观一致的湿丸,直径为4.0~4.3mm;
(5)将上述制备的湿丸置于微波干燥灭菌箱在55℃热风、箱内温度80℃条件下,干燥50~60分钟,得到干水分在5%以下的素丸;
(6)将上述素丸置于糖衣锅中包炭衣、滑石粉打光,得到丸剂。
方中当归味甘、辛,性温。归肝、心、脾经。具有补血活血,通络止痛的功效,用于血虚引起的风湿痹痛,跌扑损伤。《本草正义》:当归,其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药也;大约佐之以补则补,故能养荣养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证 。
党参味甘,性平。有补中益气、止渴、健脾益肺,养血生津的功效。用于气血不足,面色萎黄,懒言短气、四肢无力、气血虚症。《本经逢原》:清肺。上党人参,虽无甘温峻补之功,却有甘平清肺之力,亦不似沙参之性寒专泄肺气也。《得配本草》:上党参,得黄耆实卫,配石莲止痢,君当归活血,佐枣仁补心。补肺蜜拌蒸熟;补脾恐其气滞,加桑皮数分,或加广皮亦可。《本草正义》:党参力能补脾养胃,润肺生津,腱运中气,本与人参不甚相远。其尤 可贵者,则健脾运而不燥,滋胃阴而不湿,润肺而不犯寒凉,养血而不偏滋腻,鼓舞清阳, 振动中气 ,而无刚燥之弊。且较诸辽参之力量厚重,而少偏于阴柔,高丽参之气味雄壮, 而微嫌于刚烈者,尤为得中和之正,宜乎五脏交受其养,而无往不宜也。特力量较为薄弱,不能持久,凡病后元虚,每服二、三钱,止足振动其一日之神气,则信乎和平中正之规模,亦有不耐悠久者。然补助中州而润泽四隅,故凡古今成方之所用人参,无不可以潞党参当之,即凡百证治之应用人参者,亦无不可以潞党参投之。
白芍味辛、苦,性温;有小毒;归肝、脾经。有养血调经、柔肝止痛、敛阴止汗、平抑肝阳的功效。白芍常用于治疗风湿冷痛、风湿关节炎、腰肌劳损、体虚神衰、四肢抽搐、慢惊风、犬咬伤等病症。《本经》:主邪气腹痛,除血痹,破坚积,治寒热疝瘕,止痛,利小便,益气 。《别录》:通顺血脉,缓中,散恶血,逐贼血,去水气,利膀胱、大小肠,消痈肿,(治)时行寒热,中恶腹痛,腰痛。《日华子本草》:治风补痨,主女人一切病,并产前后诸疾,通月水,退热除烦,益气,治天行热疾,瘟瘴惊狂,妇人血运,及肠风泻血,痔瘘发背,疮疥,头痛,明目,目赤,胬肉 。
川芎辛,温。入肝、胆经。行气开郁,祛除风燥湿,活血止痛。常用于治疗寒痹筋挛,腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。《本经》:主中风入脑头痛,寒痹,筋挛缓急,金创,妇人血闭无子。《药性论》:治腰脚软弱,半身不遂,主胞衣不出,治腹内冷痛。《日华子本草》:治一切风,一切气,一切劳损,一切血,补五劳,壮筋骨,调众脉,破症结宿血,养新血,长肉,鼻洪,吐血及溺血,痔瘘,脑痈发背,瘰疬瘿赘,疮疥,及排脓消瘀血。现代药理研究有解痉和镇痛作用。
丹参味苦,微寒。归心、肝经。具有活血祛瘀,通经止痛,清心除烦,凉血消痈的功效。常用于胸痹心痛,脘腹胁痛,症瘕积聚,热痹疼痛,心烦不眠。《本草纲目》:活血,通心包络,治疝痛。《别录》:养血,去心腹痼疾结气,腰脊强脚痹,除风邪留热。久服利人。《药性论》:治脚弱,疼痹,主中恶;治腹痛,气作声音呜吼。近代的医学实验证明,扩张冠状动脉、改善心肌缺血状况、降低血压、安神静心、降血糖和抗菌等功效,对月经不调、经闭痛经、血行不畅、跌打损伤、疮疡肿痛、心烦失眠、心绞痛等病症有一定的疗效。丹参还具有抗血小板凝聚、降低血液黏度及调节内外凝血系统的功能,是一种安全又可靠的治疗心脏血管疾病的天然中药。
熟地黄甘,微温。入肝、肾经。具有滋阴,补血的功效。治阴虚血少,腰膝痿弱,劳嗽骨蒸,遗精,崩漏,月经不调,消渴,溲数,耳聋,目昏。《珍珠囊》:大补血虚不足,通血脉,益气力。王好古:主坐而欲起,目琉琉无所见。《纲目》:填骨髓,长肌肉,生精血,补五脏、内伤不足,通血脉,利耳日,黑须发,男子五劳七伤,女子伤中胞漏,经候不调,胎产百病。《本草从新》:滋肾水,封填骨髓,利血脉,补益真阴,聪耳明目,黑发乌须。又能补脾阴,止久泻,治劳伤风痹,阴亏发热,干咳痰嗽,气短喘促,胃中空虚觉馁,痘证心虚无脓,病后胫股酸痛,产后脐腹急疼,感证阴亏,无汗便闭,诸种动血,一切肝肾阴亏,虚损百病,为壮水之主药。熟地黄具有补血作用,生、熟怀地黄对失血性小鼠动物实验显示,生、熟地黄对造血干细胞亦有一定的增殖、分化作用,提示地黄补血作用与骨髓造血系统亦有密切相关的作用。
秦艽性苦平,微寒,归胃、肝、胆经,具有祛风除湿、活血舒经的功效,用于治疗风湿痹痛、筋脉拘挛等病症。神农本草经》:主寒热邪气,寒湿风痹,肢节痛,下水,小便利。《名医别录》:疗风,无问久新;通身挛急。《本草纲目》:秦艽,手足不遂,黄疸,烦渴之病须之,取其去阳明之湿热也。阳明有湿,则身体酸痛烦热,有热则日晡潮热骨蒸。《本草征要》:治风先治血,血行则风自灭,故疗风无论新久。
清半夏辛,温,有毒。入脾、胃经。具有燥湿化痰,消痞散结作用。主治湿痰痹阻,经络瘀滞所致的痞满、咳逆,以及痰湿阻络所致的肌肤麻木不仁等症状。半夏具有抗凝作用,可以降低甘油三酯和低密度脂蛋白的作用,能够降低全血黏度、抑制红细胞的聚集和提高红细胞的变形能力。
桂枝味辛、甘,性温。归肺、心、膀胱经。具有发汗解表、散寒止痛、通阳化气的作用。常用于风寒感冒、寒凝血滞诸痛症,肢体不温、畏寒肢冷等证。《神农本草经》:味辛温,主百病,养精神,和颜色,利关节,补中益气。为诸药先聘通使,久服通神,轻身不老。面生 光华,眉好常如童子。《本草纲目》:坚筋骨,通血脉,宜导百药,久服,神仙,不老。《本草纲目》记载:治一切风冷风湿,骨节挛痛,解肌开腠理,抑肝气,扶脾土,熨阴痹。《新修本草》:桂,味甘、辛,大热,有毒。利肝肺气,心腹寒热。
葛根味甘、辛,性凉。归肺、胃经。具有解肌、生津、升阳作用。常用于表证发热,项背强痛,热病口渴,阴虚消渴等症。《本草经疏》:葛根,解散阳明温病热邪主要药也,故主消渴,身大热,热壅胸膈作呕吐。发散而升,风药之性也,故主诸痹。伤寒头痛兼项强腰脊痛,及遍身骨疼者,足太阳也,邪犹未入阳明,故无渴证,不宜服。”《本草汇言》:“葛根,清风寒,净表邪,解肌热,止烦渴。葛根之发散,亦入太阳,亦散风寒。《别录》:疗伤寒中风头痛,解肌发表出汗,开腠理,疗金疮,止胁风痛。
柴胡味辛、苦,性微寒。归肝、胆、肺经。和解表里,疏肝解郁,升阳举陷,退热截疟。常用于阳气不能升举或不能外达肌表所致的疾病,如少阳证、下陷证、肌肤麻木不仁等症。柴胡具有升清散邪的功效,柴胡味轻,具升阳之性,能引中气升达于上。李东垣云:柴胡升也,能引中气升达于上。方如补中益气汤、调中益气汤、升阳汤等。常配伍升麻、生口芪等常治疗清阳下陷、中气不升、上气不足之证。柴胡的散邪作用,具有寒散、温散、平散、补散之作用。其寒散配黄芩、生地,温散配,平散配、生姜,补散配、熟地。
炙甘草味甘,性平。归心、肺、脾、胃经。具有补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药的功效。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
本发明公开的中药组合物主要治疗血虚络阻证的末梢神经炎,症见:肢体局部麻木疼痛,恶风怕冷,肢体抬举无力,病久或见肌肉萎缩,舌质淡白,苔薄白,脉沉细。选用纯天然中药原材料,方以当归补血活血通络,党参补中益气养血,两药合用益气养血为君。白芍养血通络,熟地黄滋阴补血,川芎行气活血止痛,丹参活血祛瘀,通经止痛,以上四药活血补血通络止痛为臣。秦艽祛风除湿、活血通经,清半夏化痰散结通经,桂枝温阳通经,葛根生津升阳,以上四药升阳活血通经共为佐,醋北柴胡升阳和解表里,炙甘草益气、缓急止痛、调和诸药为使。以上诸药合用,既能活血祛瘀通络,又能益气养血,攻补兼施,标本兼治,对于血虚络阻证末梢神经炎疗效显著,使用安全方便。
具体实施方式
实施例1
(1)称取中药原料:醋北柴胡12kg,秦艽12kg,清半夏6kg,党参14kg,桂枝12kg,炒白芍14kg,葛根14kg,川芎9kg,熟地黄14kg,当归12kg,丹参21kg,炙甘草7kg。
(2)将上述各中药原料用ZZKF-3型特大型粉碎机(烟台开发区创佳制药机械有限公司生产)粉碎成细粉,然后置于GH-200型高效三维运动混合机(哈尔滨医药化工设备有限公司生产)中混合均匀,即得粉料。
(3)取100kg上述粉料置于CH-200A型槽型混合机(甘肃天水华园制药设备科技有限公司生产)中,先加入1.5kg淀粉和13kg蜂蜜搅拌混合15min,再加入35L纯水搅拌约30min,得到软材。
(4)将上述软材置于YUJ-17B型智能高效全自动制丸机(甘肃天水华园制药设备科技有限公司生产)中拉条、搓丸,得圆整均匀、外观一致的湿丸,直径为4.0~4.3mm。
(5)将上述制备的湿丸置于HWL15-1微波干燥灭菌箱(甘肃天水华园制药设备科技有限公司生产)在55℃热风、箱内温度80℃条件下,干燥50~60分钟,得到干水分在5%以下的素丸。
(6)将上述素丸置于TG-1000糖衣锅(甘肃天水华园制药设备科技有限公司生产)中包炭衣、滑石粉打光,每100kg素丸可加入活性炭、滑石粉各0.45kg,得到丸剂。
实施例2
中药原料:醋北柴胡13kg,秦艽13kg,清半夏7kg,党参16kg,桂枝13kg,炒白芍16kg,葛根16kg,川芎10kg,熟地黄16kg,当归13kg,丹参24kg,炙甘草8kg。
丸剂的制备方法同实施例1,区别在于制丸过程中每100kg粉料使用2kg淀粉和15kg蜂蜜,40L纯水,每100kg素丸加入活性炭、滑石粉各0.48kg。
实施例3
与实施例1的区别在:醋北柴胡14kg,秦艽14kg,清半夏8kg,党参18kg,桂枝14kg,炒白芍18kg,葛根18kg,川芎11kg,熟地黄18kg,当归14kg,丹参27kg,炙甘草9kg;2kg淀粉和16kg蜂蜜,40L纯水,活性炭、滑石粉各0.5kg。
实施例4
与实施例1的区别在:醋北柴胡15kg,秦艽15kg,清半夏9kg,党参20kg,桂枝15kg,炒白芍20kg,葛根20kg,川芎12kg,熟地黄20kg,当归15kg,丹参30kg,炙甘草100kg;1.5kg淀粉和15kg蜂蜜,45L纯水,活性炭、滑石粉各0.45kg。
实施例5
与实施例1的区别在:醋北柴胡16kg,秦艽16kg,清半夏10kg,党参22kg,桂枝16kg,炒白芍22kg,葛根22kg,川芎13kg,熟地黄22kg,当归16kg,丹参33kg,炙甘草11kg;1.5kg淀粉和15kg蜂蜜,45L纯水,活性炭、滑石粉各0.5kg。
实施例6
与实施例1的区别在:醋北柴胡17kg,秦艽17kg,清半夏11kg,党参24kg,桂枝17kg,炒白芍24kg,葛根24kg,川芎14kg,熟地黄24kg,当归17kg,丹参36kg,炙甘草12kg;2kg淀粉和19kg蜂蜜,40L纯水,每100kg素丸可加入活性炭、滑石粉各0.52kg。
实施例7
与实施例1的区别在:醋北柴胡18kg,秦艽18kg,清半夏12kg,党参26kg,桂枝18kg,炒白芍26kg,葛根26kg,川芎15kg,熟地黄26kg,当归18kg,丹参39kg,炙甘草13kg;2.3kg淀粉和18kg蜂蜜,45L纯水,每100kg素丸可加入活性炭、滑石粉各0.48kg,干燥条件为50℃热风、箱内温度80℃。
对本发明的实施例4公开的中药组方进行临床药效学试验,详情如下:
1.研究对象:
多发性神经病(polyneuropathy)又称末梢神经炎是指各种原因引起肢体远端末梢神经损害,对称性感觉、运动及自主神经障碍的临床综合征。
为进一步考察本发明药物的临床疗效和安全性,我们收集近5年院内诊治的30例血虚络阻型末梢神经炎患者临床病案;年龄最小24岁,最大70岁,平均47岁;病程最短4天,最长7年。
2.诊断及分期标准
2.1西医分期
2.1.1感觉障碍:
初期常以指(或趾)端烧灼、疼痛、发麻等感觉异常或感觉过敏等刺激症状为著,逐渐出现感觉减退乃至消失。感觉障碍的分布呈手套或袜套式。少数病人可有深感觉障碍。腓肠肌等处常有压痛。
2.1.2运动障碍:
表现为肌力减退、肌张力低下、腱反射减弱或消失,个别病因(如呋喃西林)所致者反射可活跃。久病后可有肌萎缩。
2.1.3植物神经功能障碍:
肢端皮肤发凉、苍白、潮红或轻度发绀,少汗或多汗,皮肝变薄变嫩或粗糙,指(趾)甲失去正常光泽、角化增强等。
2.2中医分型
2.2.1气虚寒湿证
临床表现:手足不温,或无汗,或麻木不仁,或蚁行感觉,或肢体远端对称性肌无力,或肌张力低,或腱反射减弱或消失,或肌肉萎缩等,口淡,因劳加重,舌质淡,苔白腻,脉沉弱。
2.2.2气虚湿热证
临床表现:心胸烦热,或汗出,或麻木不仁,或蚁行感觉,或肢体远端对称性肌无力,或肌张力低,或腱反射减弱或消失,或肌肉萎缩,或肌肤溃烂等,口苦,因劳加重,舌质红,苔黄腻,脉虚弱或细数。
2.2.3瘀血寒湿证
临床表现:手足不温,或麻木不仁,或蚁行感觉,或肢体远端对称性肌无力,或肌张力低,或腱反射减弱或消失,或肌肉萎缩等,口淡,痛如针刺,舌质暗淡瘀紫,苔白腻,脉沉涩。
2.2.4瘀血湿热证
临床表现:夜间加重,或麻木不仁,或蚁行感觉,或肢体远端对称性肌无力,或肌张力低,或腱反射减弱或消失,或肌肉萎缩,或肌肤溃烂等,口苦,痛如针刺,舌质暗红瘀紫,苔黄腻,脉浮涩。
2.2.5 气滞血瘀证
临床表现:急躁易怒,或夜间加重,或肢体麻木,或肢体远端对称性肌无力,或肌张力低,或腱反射减弱或消失,或肌肉萎缩等,因情绪异常加重,痛如针刺,舌质暗红瘀紫,苔黄腻,脉弦或涩。
2.2.6 阳虚痰热证
临床表现:手足不温,或手足烦热,或麻木不仁,或蚁行感觉,或肢体远端对称性肌无力,或肌张力低,或腱反射减弱或消失,或肌肉萎缩等,口淡,舌质淡红,苔黄腻或厚,脉沉弱或滑数。
2.2.7 血虚络阻证
临床表现:肢体局部麻木疼痛,恶风怕冷,肢体抬举无力,病久或见肌肉萎缩,舌质淡白,苔薄白,脉沉细。
疗效标准:
治愈: 临床症状、体征消失,肢体感觉和运动能力完全恢复。
显效: 临床症状、体征明显减轻,肌力增强,肌萎缩明显改善,肢体疼痛,麻木程度较治疗前明显减轻。
有效: 临床症状、体征稍有所减轻,肢体疼痛,麻木感觉有所减轻。
无效: 临床症状、体征均依旧,完全没改善。
使用方法:
以养血活血,通经通络为治疗原则,以实施例4所述组方制备的丸剂,口服,一次9g,一日3次;2周为一个疗程。
疗效结果:
临床疗效结果:
治疗后,治愈12例,显效13例,有效5例,无效0例;治愈率40.0%,显效率43.3%,有效率16.7%,无效率0,总有效率100%。详细结果如下表1。
副作用反应
所有患者在治疗中,均未出现明显不良反应。
结果表明,本发明中药制剂通过中医药辨病与辩证相结合的原则,攻补兼使,标本同治,用于治疗末梢神经炎疗效显著、治愈率高且不易复发,同时避免了药物治疗带来的副作用,具有一定的优势,值得临床推广和应用。
临床病案1
2018年11月29日 星期四
魏某某,女,61岁,全身多处皮肤麻木5年余,右手无力半年。5年前出现右大腿外侧麻木,渐出现双手麻木无力,不能抱孙子,不能捏饺子,右颈肩部疼痛,以右手为甚,右手、右肘功能受限。舌质淡红,苔薄白,脉沉细。查右前臂、右手大小鱼际萎缩,右上肢皮肤感觉减弱,肱二头肌、三头肌肌腱反射减弱,右颈肩部肌肉压痛。查风湿三项正常,风湿多肽15项正常,血常规正常,肝功能正常,肾功能正常。来我院就诊后服用本发明实施例4制备的丸剂,每日3次,每次9g。
2018年12月13日星期四
电话随访,患者全身皮肤麻木症状较前有所减轻,与患者沟通后决定为患者邮寄本发明实施例4制备的丸剂,同时继续按照每日3次,每次9g,温水送服。嘱其加强功能锻炼,中药继服。
服用20天,左手麻木消失,右手麻木症状减轻,右腕关节疼痛消失,双手握力增加,双肘关节功能如前,纳眠可,服中药期间大便前腹痛,小便调,舌质淡红,苔薄,脉沉细。继续服用本发明实施例4制备的丸剂,每日3次,每次9g。
服药3个疗程,诉麻木基本消失,疼痛减轻,仍有右手大小鱼际肌肉萎缩,口苦不渴,眼睛干涩疼痛,舌质淡红,苔薄白,脉沉细。继续服用本发明实施例4制备的丸剂,每日3次,每次9g。
一个半月后复诊,右大腿外侧麻木消失,右手较前可以捏饺子,肌力增加,右前臂、右手大小鱼际肌肉较前丰满,与对侧相比稍弱。舌质淡红,苔薄黄。脉沉细。继续服用本发明实施例4制备的丸剂,每日3次,每次9g。嘱患者继续服两个疗程,后患者全身麻木症状基本消失,无力症状较前明显改善,随访半年患者上述症状未再复发。
临床病案2
秦某,女,32岁。自诉2021年4月始发病,初期感觉双手指末端有烧灼疼痛,有时出现麻木现象,遇寒后病情加重,双手时有苍白或潮红现象。经多家医院诊断为多发性末梢神经炎,虽曾服多种药物及针灸理疗均未见效,并有加重之势,故于2021年5月3日前来我院求医。经常规检查均正常,患者双手时红时白,舌苔薄白而滑,舌质淡,脉浮缓或沉紧。辨证为寒凝络脉。治以通阳散寒,活血通络。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g。用上方丸剂3三个疗程后,自觉双手时有蚁行之感,临床症状较之前有所减轻。后继服上方丸剂5个疗程后痊愈,随访半年未见复发。
临床病案3
王某,男,45岁,2021年3月6日初诊,8个月前自感双下肢膝关节以下麻木、发凉,如戴袜套。平素时有头晕、胸闷,急躁易怒、纳差乏力,舌质暗红,苔薄白,脉弦。嗜酒20年。查体:双下肢远端痛、温觉减弱,肌力尚正常,双下肢腱反射减弱,腰椎CT未见异常。西医诊断:末梢神经炎(酒精中毒性);中医诊断:麻木,证属血行不畅,瘀阻脉络。治以活血疏筋,温经通络。处方我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g。经6周后,麻木症状减轻,继服10周后双下肢麻木症状消失,随访3个月未复发。
临床病案4
患者张某某,女,56岁。2021年6月13日初诊,其在饭店工作,双手经常下水,两年前开始出现双手指麻木、僵硬、触觉减退,如戴手套,指肤角质增厚等。经多方治疗未效,近两月症状尤其明显,遂来我科求治,刻下:舌质淡,苔白腻,脉弦细。中医诊断:肌痹(气血痹阻,久病夹虚)西医诊断:末梢神经炎。中医治则给予活血化瘀,舒筋通络治疗,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g。其2021年7月17日复诊,患者双手指麻木僵硬明显消失,触觉接近正常水平,追溯病人有两年多的手指麻木病史,叮嘱其减少服用次数,改为每日2次,早晚温水送服,继续服用,巩固疗效,嘱咐日常自护。2021年8月22日患者服完药后随访,欣喜告曰:其病康复,手指活动自如。病程两年的末梢神经疾患告愈。
临床病案5
韩某,男,69岁,2021年5月27日初诊,主诉:双脚底麻木1年半,伴脚心,脚指头麻木。现病史:患者自诉患病一年半多,腿麻行走困难,在当地各大医院治疗多次基本无效。每次去医院输液10多天,效果甚微,出院回去还是原样。查体:大便5-6天一次,干燥,小便少,尿时痛,睡眠可,汗可。最严重的时候,双脚底发麻不能走路,脚底周围发黑,脚指盖也已经开始变黑。纳少,吃饭过程中会呕吐,反酸。这种情况有半年时间。舌体淡胖,舌苔厚腻微黄。脉沉紧。诊断:痹症(西医叫末梢神经炎)辨证:血虚络阻证。治法:养血活血,通经通络。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g。
第一天:查房患者诉双脚发热,左脚较甚,麻木感较前稍缓解,嘱患者继续按时服药。
第二天:脚部发热、发胀但是麻木完全消失,走路更加灵活。治疗方案不变。
第三天麻木感消失,心里感觉脚有点肿,但实际上脚没有肿,但是有脚底踩棉花的感觉。继续当前治疗。
第四天:麻木感消失,有胀感,有踩棉花感。嘱其睡前用温水泡脚,促进血液循环,继续当前治疗方案。
第五六天,脚胀感减轻,脚底反应僵紧,患者说发硬,脚底有寒气往外冒,脚的指甲盖黑色有所减轻,继续当前治疗方案。
第七八九十天,每天改善更加明显,脚底发硬消失,吃饭改善,大便改善,脚底发凉还有一点,走路基本正常。最明显的是原来黑色的皮肤逐渐褪去,长出新肌肤,整体颜色在不断变淡,效果显著。病人非常感谢,也非常惊叹,没有想到有这么好效果,赞叹医术精湛。鉴于患者患病时间较长,嘱患者院外继续服用一个疗程,以巩固其疗效,随访半年,患者上述麻木症状逐渐消失,未再复发。
临床病案6
刘某,男,41岁。2021年3月12日诊。半年前不明原因出现右脚外侧半边麻木,针刺样疼痛,某医院诊为末梢神经炎,予以消炎痛、激素、维生素、中药等治疗无效,病情逐渐加重,特来就诊。刻诊,右脚外侧脚背及趾尖半边麻木,针刺样疼痛,站立、行走痛甚,睡眠欠佳,饮食尚可,口微渴,干燥,不欲饮,两便正常。查:局部不红不肿,触觉、痛觉减弱,舌质淡,边有小瘀斑,苔薄白,脉弦细涩,诊为末梢神经炎。辨证:气血瘀滞,肢末不荣。治法:活血祛瘀,通络止痛,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g。服药6周后,麻木、疼痛明显减轻,嘱患者继续服药至彻底治愈,后共服药10周而痊愈。后随访半年麻木症状未再复发。
临床病案7
赵某,女,47岁,2021年5月31日诊,主诉:左侧手足麻木4天。现病史:4天前因劳累出现左侧手足麻木,伴有头晕、疲乏,睡眠尚可,无颈部僵硬感。记忆力尚可,纳可,大便调。既往史:既往体健;过敏史:无;舌脉:舌体适中,苔薄白略腻,脉细沉。辅助检查:全血五分类提示HGB90g/L,MCV64.8fl。初步诊断:头晕;缺铁性贫血;末梢神经病(末梢神经炎);气血两虚证;瘀阻脉络;维生素C缺乏性贫血。治疗给予西药:琥珀酸亚铁片(0.1g*20)1盒/0.1gtid、维生素C片(0.1g*100)1瓶/0.1gtid1;中成药给予院内丸剂,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。2021年7月7日复诊,症状描述:左侧手足麻木基本缓解,仍有晨起口干口粘,乏力,睡眠可,纳可,大便不成形。嘱患者再次服药2周后,左手足麻木症状较之前明显好转,患者对疗效满意,嘱其继续服药1周。后在对其随访发现患者半年内手足麻木症状未再加重。
临床病案8
杨某,女,28岁,农民,因有慢性胃炎于2021年4月听他人介绍口服吠喃哇酮治疗。1个月后患者出现四肢对称性手套、袜子样感觉障碍,伴有手足轻度肿胀,触痛明显,行走困难。于2021年5月21日来我院就诊。查体:脉搏78次/分,呼吸频率20次每分,血压120/80mmHg,患者神志清,瞳孔等大等圆,对光反射正常,颈软,心肺听诊正常,腹部无异常,四肢肌张力降低,双上肢前臂中部至手指末端及双下肢膝关节以下触觉减退,痛觉过敏,胧三头肌反射及膝反射正常,其他病理反射未引出。辅助检查:血RT(一),尿RT(一),颅脑CT扫描未见异常。诊断:多发性末梢神经炎。治疗:给予口服维生素B1、地巴哇,肌注维生素B12、ATP等药物,并结合理疗,疗效欠佳,查体发现:患者肢体局部麻木疼痛,恶风怕冷,肢体抬举无力,病久或见肌肉萎缩,舌质淡白,苔薄白,脉沉细。中医诊断:血痹;中医证型:血虚络阻证;中医治疗原则:养血活血,通经活络。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。用上方丸剂3周后,自觉双手时有蚁行之感,临床症状有所减轻。后继服上方丸剂5周后痊愈,随访半年年未见复发。
临床病案9
患者张某,女,61岁,农民,2021年6月11日就诊,患者3个月来口干多饮四肢乏力,饭量正常,体重减轻10斤。1个月前出现四肢麻木,视物模糊,会阴部不适。头皮发麻发紧发热无压痛5~6年,偶有眩晕。小便尿黄有泡沫。排便正常。双肺闻及湿罗音。发病以来患者胸闷,失眠,睡眠质量下降。无畏冷、发热;时常怕热、烦躁、甲状腺肿大。膝、跟腱、桡骨骨膜反射存在,无运动功能障碍、对称性肢体软瘫。昨日外院体检空腹血糖浓度14.1mmol/L,服药治疗,具体不详。患者自述患有风湿,颈椎麻木前年加剧,并服药治疗,具体不详。患者平素体健,并无“肝炎、结核”等传染病史,无药物以及实物过敏史。无手术外伤史,无输血史。预防接种随当地进行。2年前外院检查有骨质增生,具体用药量不明。西医诊断:2型糖尿病末梢神经炎;中医诊断:血痹;中医证型:血虚络阻型;西医以药物降血糖、扩血管为主;中医治疗原则以养血活血,通经活络;我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。患者服药1个疗程后,四肢麻木症状较之前有所好转,患者对疗效满意,嘱其继续服药2个疗程。后在对其随访发现患者半年内手足麻木症状未再加重。
临床病案10
患者李某,女,25岁,2021年4月6日初诊,患者产后2月左右,逐渐感觉四肢麻木不仁,以至不能持物,下肢站立困难,但全身无关节肿痛,乏困无力,头晕出汗,心悸失眠。曾被某医院按关节炎治疗一段时间,结果病不减反而增重。查体:四肢远端浅感觉痛觉均障碍,各种腱反射亦减弱,关节无畸形肿胀,舌体瘦小,舌质淡白,脉沉细,无力。西医诊断:多发性末梢神经炎;中医诊断:血痹;证型:血虚络阻证;方我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。5月5日复诊:四肢麻木不仁诸症基本消失,并能参加轻体力劳动,嘱其适量逐步锻炼,不适及时就诊。1年后随访,患者身体健康并能正常参加劳动。
临床病案11
李某某,男,56岁,教师 患者患I型糖尿病8年,2021年10月8日,以双下肢麻木1年余,时轻时重,工作烦累时加重。曾在多家医院就诊,都以糖尿病末梢神经炎为其诊断,长期服用阿司匹林肠溶片,甲钴胺片及其它多种维生素,其感觉异常稍有好转。近儿月来,由于工作烦累,双下肢麻木加重,持续时间较过去延长,有如踏棉垫感,人夜伴疼痛,彻夜难眠、烦渴、躁怒,而求治于中医科,症现:舌质暗红、苔少、脉细涩、双下肢无凹陷性水肿、皮肤色泽正常,各种检查未见异常,检查排除风湿症,测空腹血糖:6.5mmol/ L ,综合分析西医诊断:糖尿病末梢神经炎;属中医“消渴”“痹症”范畴。辨为气虚血滞,脉络瘀阻证。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。
2021年11月8日复诊:肢休麻木疼痛明显减轻,无踏棉垫感,入夜可以安睡,余症几近消失。空腹血糖6.8mmol/ L。考虑患者病程较长,嘱其继服30天,后患者诸症基本消失,停药观察3个月未见复发。嘱其携带本发明实施例4制备的丸剂,减少服用频率,改为早、晚温水送服,继续服用两周,以巩固其疗效。后续随访半年患者麻木症状未复发。
临床病案12
陈某,男,汉族,70岁,农民。该患者于2021年2月22日因“手足无力3个月”入我院神经内科住院治疗。入院诊断:入院诊断:1、手足麻木症;2、阵发性抽搐;3、下肢无力;4、肌力2级:0/2级(肌张力正常);5、轻度麻痹;6、中度麻痹;7、深感觉障碍;8、感觉减退及(部分)触觉缺失及(部分)反射迟钝。双下肢肌力0级(3-4级)。肢体远端感觉缺失呈紫蓝色至紫红色(无感觉缺失)。双手能轻微握拳。无出汗及触地痛。双手握拳时腕部有轻度疼痛。患足内有足趾外翻畸形者需作足趾屈曲试验及趾屈伸试验,足背有烧灼感或刺感不能忍受时可给予小量抗生素口服或静脉注射布洛芬或双氧水缓解疼痛。外周神经炎。后足三步连足背出现疼痛及脚趾麻木感伴瘙痒感(夜间尤为明显);发作1~2天后逐渐加重病情以脚趾为主要表现不能行走而致不能下地行走,经药物治疗无效后转入神经内科治疗。现病史:患者)3年前出现一侧足趾萎缩并患有足底麻木症状2年余现下肢感觉减退及刺痛及麻木感;于医院行相关检查:血糖正常;头颅 CT示:双侧颅底血管瘤压迫下肢动脉引起下肢动脉硬化闭塞症(DIC);左侧颞骨骨折伴右侧颞叶枕骨大孔;右侧颞骨大孔骨结节炎;左侧眼眶骨骨膜及脉络膜病变;硬膜下血肿伴血栓形成;脑积水伴多发性脑积液;脑梗塞术后后遗症伴发头晕4天入院诊断:1.癫痫(偏瘫)2.四肢瘫3.周围神经炎3.脑积水5.脑血栓及肺栓塞5.脑梗死6.脑梗塞后昏迷4天(前);脑出血伴呼吸循环障碍5.呼吸衰竭(休克)7.心源性休克。中医诊断:血痹;证型:血虚络阻证;我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。服用6周后,麻木症状较前有所减轻,嘱继服10周后患者双下肢麻木症状消失。随访3个月未复发。
临床病案13
吕某某,男,46岁。2021年5月份就诊,就诊时患者主要表现为四肢肿胀,肌肉酸疼十多天,西医诊断为末梢神经炎。其人身体瘦高,面色淡白,手臂沉重,抬手诊脉亦觉费力。恶风怕冷,而且身有汗但四肢无汗。舌质淡白,脉沉细。属中医血痹症的范畴。予患者中药丸剂治疗,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。初次服药后患者四肢得微汗出,肌肉酸痛有所缓解。服药3周后,四肢麻木病证较前有所减轻;嘱其继服5周后患者麻木症状较前明显减轻。嘱患者继续再服10天以巩固疗效。随访半年患者未复发。
临床病案14
邢某,男,50岁,2021年10月3日初诊。患者于3个月前因淋雨后发热,关节疼痛,周身不适,神疲,四肢乏力,自服感冒药治疗未效。次日赴某市立医院诊治,诊为感冒,予以输液治疗,仍未效。6月27日起下肢红肿、无力,活动困难,某医院按“风湿病”治疗,仍未效。因病情进展,经我院门诊诊断为“多发性神经炎”,予以中西药治疗,病情得以控制,未继续发展。刻诊:手足不温,肢体痿软少力,麻木不仁,面色萎黄、语低声微,少寐,面浮少泽,神疲少言,食少便溏,舌淡胖,脉细弱无力。西医诊断末梢性神经炎,中医诊断为痿证(脾胃虚弱,气血两虚)。治当健脾益胃、调补气血,通经活络。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。服药2周后复诊,患者四肢逐渐有力,麻木不仁明显减轻,舌淡苔白,脉沉缓。继续当前治疗方案服药10天。三诊患者麻木基本消失,四肢有力,面色红润,舌脉正常。嘱患者逐步适量增加功能锻炼,如有不适及时就诊。随访半年未再复发。
临床病案15
沈某,女,35岁。2021年5月就诊。患者产后半个月,先觉上肢麻木,后觉下肢麻木,有时酸楚。现有症状:上下肢常觉麻木不仁、酸楚、恶风怕冷、时己初夏、棉衣着而不能脱、多汗、面无华色、精神疲倦、头眩心慌、舌淡苔白、脉象虚大。病证辨析:西医诊断:末梢周围神经炎;病属中医血痹范畴.辨为气血不足,血虚络阻之血痹病。病因病机分析:患者产后半月,正值机体气血亏虚之时,易感受风冷,形成血瘁治宜益气养血,祛风散寒,调和营卫。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。服药5个疗程后,肢体麻木、酸楚诸症乃除,说明风寒得祛,气血和调,遂告痊愈。随访半年未复发。
临床病案16
张某,男,35岁,患末梢神经炎两年(因治疗慢性胃炎,服用阿莫西林、痢特灵、甲硝唑引起).手指麻木、刺痛感(开始为一侧,后来发展到双侧),双足趾不时有电击样灼痛、针麻感,膝盖以下麻木(久坐后后更厉害,似无数条虫子爬一样),用手触摸皮肤,好像隔层布一样,用力搔抓不知痛痒。身体皮肤不定位的有一小块灼痛感,火烧一样,晚上加重,疼痛发作时彻夜难眠,疼痛难忍,使用杜冷丁、曲马多、卡马西平等强效止疼药也难奏效。双脚底板木胀不适、发紧、怕凉。自诉上述症状每于受凉,劳累过后加重。相关化验检查正常,肌电图检查也基本正常。长期服VB1、B6、B12、甲钴铵等药,曾作针炙、理疗、熏洗治疗。并服中药30余剂症状不缓解。2022年4月来我院治疗,查体:患者神志清,精神一般,饮食胃口一般,睡眠差,大小便可,肢体局部麻木疼痛,恶风怕冷,肢体抬举无力,双下肢肌肉萎缩,舌质淡白,苔薄白,脉沉细。本病西医病名为末梢神经炎,隶属于中医学血痹范畴,辨其证属:血虚络阻证,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。服药3个疗程后,麻木症状明显减轻;嘱其继续用药巩固治疗,共服药5个疗程后治愈。后随访半年患者麻木症状未再复发。
临床病案17
陈某,男,58岁,患周围神经炎三年,手足麻木,疼痛麻痹(患者糖尿病10年)。症状:手指胀木,好似冻伤一样,麻木过后胀痛。双脚麻木,脚板如有物挤压、紧缩感。手足冰凉,不出汗,尤以两足为甚,时值夏天,仍穿棉袜和棉鞋,尚有冷感。麻木从手指和脚趾起,上行过腕、肘和踝、膝关节到达前臂和大腿,尤其是踝关节以下毫无痛痒知觉。曾用中、西药多方治疗,上肢症状减轻,下肢症状依然。以后渐出现小腿肌肉轻度萎缩变细、感觉行走困难,无力感。此次病情加剧,曾住院治疗一个月,效果不明显。来时患者查体:神志清,精神一般,纳一般,睡眠可,大便一般,小便发黄浑浊,肢体局部麻木疼痛,恶风怕冷,双下肢抬举无力,小腿肌肉萎缩,舌质淡白,苔薄白,脉沉细。本病西医称为末梢神经炎,隶属于中医学血痹(血虚络阻证)的范畴。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。两周为一个疗程,服药一个疗程后,麻木较前有所减退,手、足由凉转为温热出汗,足部知觉恢复。嘱患者继续服用两个疗程,后复诊得知患者,麻木症状基本消失,仅双脚仍不时有针刺或触电样感,继续服药治疗,共服药5个疗程,小腿肌肉萎缩明显好转,麻木感完全消失,感觉腿部力量增加,基本和以前正常时一样。随访半年未再复发。
临床病案18
赵某,男,42岁,重庆市人,2021年来我院就诊。病情病史:四肢阵发性剧痛难忍,间隔性发作,针刺无感觉,麻木。治疗经历:2020年7月12日突然发病,主要表现为四肢阵发性剧痛难忍,每隔10min~30min发作1次,牙咬毛巾或衣物在床上翻身打滚嚎叫不止,经当地医院治疗无效。13日上午出现四肢不能行动,呈瘫痪状态。即去某大医院神经科检查,两下肢股部至足趾针刺毫无感觉,麻木不仁。两上肢肘部关节至手指尖针刺感觉消失,麻木不仁。实验检查及腰椎x摄片均正常,诊断为多发性神经炎。治疗一个月后,效果不明显。
经朋友介绍,了解到我院中医治疗末梢神经炎很出名,于是在网上搜索进行预约专家,来到我院治疗,经过系统检查诊断确诊为:末梢神经炎。脉诊:沉细无力,两尺尤虚。舌淡白,苔薄腻。诊断:肝肾不足,气虚血瘀,瘀阻脉络。治疗用药:我院专家结合赵某的病情,决定予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。并为其推荐了“超低频电磁导入技术”经过2个疗程的治疗,赵某的病情得到改善,身体的麻木减轻。又继续服用,其四肢疼痛麻木消失,活动如常,为了巩固治疗,又嘱其坚持服用治疗了2个疗程,直至病情彻底消失。随访半年患者病情已经得到了改善,并没有复发的迹象。
临床病案19
张某某,男,24岁,于2021年5月7日,因自服甲胺磷农药中毒在我院住院治疗7天后好转出院。两周后突然出现四肢末端麻木, 双下肢萎软无力,故又到我处诊治。患者当时肢端麻木,有手套样、袜套样感觉障碍,四肢萎软无力,有对称性胀痛,舌质淡,脉沉细。临床诊断为多发性末梢神经炎;中医诊断为血痹。经综合讨论我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。2021年6月5日复诊,患者四肢麻木症状明显减轻,嘱其继服药10天以巩固疗效,用药结束后随访询得知患者症状基本恢复正常,嘱其逐步适量功能锻炼。随访半年未再复发。
临床病案20
杨某某,男,35岁,于2021年6月15日前来我科就诊,患者患末梢神经炎两年.手指麻木、刺痛感(开始为一侧,后来发展到双侧),双足趾不时有电击样灼痛、针麻感,膝盖以下麻木(久坐麻木加重,似虫爬一样),用手触摸皮肤,如隔层布一样,用力搔抓不知痛痒。身体皮肤不定小块部位灼痛感,火烧一样,夜间加重,疼痛发作时彻夜难眠,疼痛难忍,使用杜冷丁、曲马多、卡马西平等强效止疼药也难奏效。双脚底板木酸胀不适、发紧、怕凉。自诉上述症状每于受凉,劳累过后加重。相关化验检查正常,肌电图检查也基本正常。长期服VB1、B6、B12、甲钴铵等药,曾作针炙、理疗、熏洗治疗。并服中药30余剂症状不缓解。本次治疗以补气活血,化瘀通络为主,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。中医讲究“正气旺盛,气血自通”这是用药的关键。首次服药3个疗程,症状明显减轻,继续用药巩固治疗,共服5个疗程停药。后随访半年,患者四肢麻木症状未再复发。
临床病案21
司某某,女.48岁,患者于2021年11月4日因"双下肢麻木,疼痛,行走圈难半月"来本院就诊。患者半月前受风后,出现双下肢麻木,疼痛,行走困难,时有摔倒,伴烦躁,易汗出,就诊于省中医院,按更年期综合症治疗。无效,后诊为末梢神经炎,予营养神经治疗,未见明显疗效。近3天上述症状加重,并出现双上肢麻木不适,为求进一步治疗遂来我门诊诊治。现症见:神志清,精神差,双上肢麻木不适,疼痛,行走困难,舌体瘦薄,苔薄白,脉沉细。西医诊断为:多发性末梢神经炎;中医诊断:血痹(血瘀络阻证);治以养血活血,温经通络为主。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。2022年1月8日复诊,上述症状明呈好转。嘱患者继服2周,春节后停药,正月初八开始上班。2022月2月20日复诊,见病人完全康复。后随访半年未再复发。
临床病案22
患者马某,男,45岁,广东人。职业:生意人,于2年前无诱因的开始出现双手双足麻木,寒凉,疼痛,疼痛时有抽搐感,夜间加重,无法入睡,呈手套式和袜套式样的麻木发作,未做过肌电图等检查,一直用营养神经的西药和中药等治疗,均未见好转,病情仍逐渐进展,近2月症状较前加重,夜间疼痛无法入睡,病人已无法从事任何的劳动。经朋友介绍来到我院进行治疗。
查体情况:1、两下肢股部至足趾针刺毫无感觉,麻木不仁。2、两上肢肘部关节至手指尖针刺感觉消失,麻木不仁。3、肢端皮肤发凉、发绀,有轻微出汗障碍,皮肤开始变粗糙变薄;肌力减退、肌张力低下,有轻微肌肉萎缩的征兆,患者神志清,精神一般,纳眠可,大小便可,舌质淡,苔薄白,脉沉细。腰椎X摄片未见明显异常。西医诊断:末梢神经炎。中医诊断:血痹(血瘀络阻证);治疗西医以营养神经药物治疗为主;中医以养血活血,通经活络为原则,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。服用4周后,患者双手足麻木症状有所减轻,嘱其继续服药4周以巩固疗效,1月后患者前来复诊,询问得知患者四肢末端麻木症状明显减轻,再给予患者3个疗程用药。后随访半年患者双上下肢麻木症状未再出现加重情况。
临床病案23
林某某,女性,56岁,工人。半年前出现左下肢麻痹至今,四个月左右前出现左膝盖疼痛,输液治疗后疼痛缓解些。2021年2月20日于仁化县人民医院住院治疗,疗效欠佳。出院后左下肢麻痹严重,同时右下肢也出现轻微麻痹。在本地人民医院住院诊断:左足末梢神经炎,原发性高血压,符合性高血脂症。持续吃脑栓通,降压药4个月至今。查体发现:患者神志清,精神一般,睡眠较差,大小便一般,舌淡红,苔薄白,脉沉细;西医诊断:周围性末梢神经炎;中医诊断:血痹,中医证型:血虚络阻证。经综合分析后决定给予中药治疗,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。患者服药4个疗程后,双下肢麻木症状较前有所减轻,嘱患者继续服药三个疗程,服药完后后患者前来复诊得知,患者左下肢麻木症状明显减轻。后随访半年得知,患者患肢麻木症状未再出现加重情况。
临床病案24
梁某,男,54岁,郑州人。有7年多末梢神经炎病史,虽多次服用中西药,但没有取得预期治疗效果,近因病证加重而前来诊治。刻诊:下肢疼痛,麻木不仁,对称性肌无力,肌肉轻微萎缩,时如蚁行感觉,因劳加重,口淡不渴,舌淡白,苔薄白,脉沉细,虚弱无力。诊断为末梢神经炎,中医诊断:血痹(血虚络阻证),治当养血活血,通经通络;给予中药治疗,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服。二诊:下肢疼痛略有减轻,继续服药半月。三诊:麻木较前好转,继服前方10天。四诊:口淡不渴、乏力症状消除,下肢疼痛明显减轻,续前方6天的量。五诊:疼痛基本得到控制,以前方6天的量。为了巩固疗效,以前方继续服用20天,减少服药频率,改为早、晚温水送服,每次9g,治疗3个月。随访1年症状未再复发。
临床病案25
张某,男,35岁,患末梢神经炎两年(因治疗慢性胃炎,服用阿莫西林、痢特灵、甲硝唑引起).手指麻木、刺痛感(开始为一侧,后来发展到双侧),双足趾不时有电击样灼痛、针麻感,膝盖以下麻木(久坐后后更厉害,似无数条虫子爬一样),用手触摸皮肤,好像隔层布一样,用力搔抓不知痛痒。身体皮肤不定位的有一小块灼痛感,火烧一样,晚上加重,疼痛发作时彻夜难眠,疼痛难忍,使用杜冷丁、曲马多、卡马西平等强效止疼药也难奏效。双脚底板木胀不适、发紧、怕凉。自诉上述症状每于受凉,劳累过后加重。相关化验检查正常,肌电图检查也基本正常。长期服VB1、B6、B12、甲钴铵等药,曾作针炙、理疗、熏洗治疗。并服中药30余剂症状不缓解。2007年4月来本专科寻求治疗,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服,两周为一个疗程。首次服药两个疗程,症状明显减轻,继续用药巩固治疗,共服中药35天治愈。后随访半年患者麻木症状未再复发。
临床病案26
蔡某某,男,58岁,患周围神经炎三年,手足麻木,疼痛麻痹(患者糖尿病10年)。症状:手指胀木,似冻伤,麻木过后胀痛。双脚麻木,脚板如有物挤压、紧缩感。手足冰凉,不出汗,尤以两足为甚,时值夏天,仍穿棉袜和棉鞋,尚有冷感。麻木从手指和脚趾起,上行过腕、肘和踝、膝关节到达前臂和大腿,尤其是踝关节以下毫无痛痒知觉。曾用中、西药多方治疗,上肢症状减轻,下肢症状依然。以后渐出现小腿肌肉轻度萎缩变细、感觉行走困难,无力感。此次病情加剧,曾住院治疗一个月,效果不明显,为求进一步治疗,遂来我门诊就诊。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服,2周为一疗程。4个疗程后,麻木较前有所减轻,减退,手、足由凉转为温热出汗足部知觉恢复。仅双脚仍不时有针刺或触电样感,继续服药治疗,共计服8个疗程,小腿肌肉萎缩明显好转,麻木感基本消失,感觉腿部力量增加,基本和以前正常时一样。随访半年上述症状未再加重。
临床病案27
陈某,女,52岁,2021年7月因臀部多发性疖肿而服用百炎净,每次0.96 g, 2次/d,连服10天,疖肿痊愈停药后半个月出现双足、双手趾指端发痒,继之出现双手、双足背皮肤有蚁走感,双手麻木疼痛、以针刺样、烧灼痛为主,尤以指趾端为甚。因疼痛难忍,不能触摸,并逐渐加重而住院,查体:患者四肢末端,及部分肢体上端麻木,疼痛觉降低,患者神志一般,精神一般,饮食可,睡眠差,大小便一般;望诊:患者舌质淡,苔薄红,脉沉细。西医诊断为磺胺药物引起多发性末梢神经炎;中医诊断:血痹(血虚络阻证)。治疗西医予大剂量B族维生素、烟酸、能量合剂及静滴低分子右旋糖醉等药物为主;为求综合诊治,随来我院,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服,2周为一个疗程。共服药6个疗程,期间患者佐以高压氧治疗。三个月后患者麻木症状好转出院。后随访半年患者未再复发。
临床病案28
路某某,男,47岁,2022年2月5日就诊,患者手麻多年。现病史:3年前,一次着凉受寒后开始加重,双手麻木,双足麻木,似蚁爬样感觉,且有针刺样疼痛,夜间侧身睡觉,胳膊受压后症状加重,晨起双手聚胀,僵硬感。严重时走路如踩棉絮样,感觉麻木不灵敏。右半身麻木较重,有时手拿筷子吃饭,也觉麻木不适。医院各项检查如下:高血压(150/100mmHg)、胆固醇,甘油三脂均偏高,血流变检查高血粘度,CT,核磁振检查正常,腰4-5椎关节增生,肌电图检查正常。(医院初诊为:1.脑供血不足?2.末梢神经炎?)曾服用血栓通胶囊,活络丸,天麻胶囊,丹参、脉络宁注射液、弥可保,甲钴铵,维生素B1,B12,培他啶、654—2,效果不明显。为求综合治疗,1周前经我门诊经分析患者症状诊断为末梢神经炎,中医诊断:血痹;入住我科后决定给予中药治疗,予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服,两周为一疗程,三个疗程后患者双手,双足麻木症状明显减轻,嘱患者再服两个疗程,后随访得知服药后患者麻木症状基本消失,效果良好。后随访半年患者麻木症状未再复发。
临床病案29
郝某某,女,44岁。患末梢神经炎四年,刚开始手指尖发麻,经常服用维生素B类、弥可保等药,效果不明显。一次感冒发烧过后,症状突然加剧,麻木延伸至全身:四肢麻木、紧箍感,头皮麻,感觉头皮加厚,头皮痛痒觉明显减弱。口唇、舌头发麻、胸胁发紧、发皱、呼吸不畅、脚底板发硬,如踩鹅卵石一样,双脚、下肢烧灼感、火烧火燎、极度不适!走路不稳、下肢萎软无力。平躺、久坐、身体任何一个部位只要压迫时间长,都会引起麻木加重。平躺在床上,自觉身体下坑坑洼洼不平,有东西嗑一样。走路脚下如垫东西,高低不平。四肢好像不过血一样。精神差、困乏、易疲倦,曾用西药、输液、打针、住院治疗一个多月没有效果。医院检查化验各项基本正常,肌电图轻微改变,显示神经轻度损害。后又做针炙、拔罐、按摩治疗,并服中药50余剂,病情不见好转。
2021年7月来我院治疗后,我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服,两周为一个疗程,五个疗程后,麻木症状较前改善明显,身体麻木减轻,足底异物感不显,走路平稳,四肢温热,身体不再畏寒,精神好。但身体受压久后仍有麻木感,继续巩固治疗两个疗程,余症完全消失,效果良好。后随访半年上述麻木症状未复发。
临床病案30
王某,女,30岁,自述双手麻木1年。现病史:患者1年前因在冬天长期用凉水洗衣服引起双手麻木等不适,白天稍轻,夜间为甚。在县医院被诊断为末梢神经炎,经服药(甲钴胺和舒筋和血丹等)和针灸治疗,均未见成效。冬季又到,患者病情有加重之象。经人介绍,前来求诊。患者甘油三酯血脂稍高(2.32mmol/L),空腹血糖正常(4.51mmol/L),颈椎正侧位片也未有异常发现。患者面色微黄少华,喜热微恶寒,双手麻木至腕关节以上,颜色无变化,肌力尚可,手指无肿胀,握之有寒凉感,对划痕等刺激反应迟钝,舌淡有瘀点、苔白滑腻,脉沉滑。辨证为血痹(气血不足,阳虚感寒,寒凝经脉);治宜温阳补气,养血活血,通经活络。我院予以患者服用本发明实施例4制备的丸剂,每日3次,每次9g,温水送服,两周为一疗程。服上药两个疗程后,症状较前有所减轻。考虑到患者病情过久,为巩固疗效,故又嘱再服3周,服完后,患者麻木症状明显减轻。为求更好治疗效果,嘱患者再服10天,减少每天服药频率,改为每日两次,早晚温水送服。后随访半年得知患者患者服药结束后,麻木症状基本消失,四肢感觉恢复至正常水平,且未再复发。
以上所述的仅是本发明的优选实施方式,应当指出,对于本领域的技术人员来说,在不脱离本发明整体构思前提下,还可以做出若干改变和改进,这些也应该视为本发明的保护范围。
Claims (4)
1.一种治疗血虚络阻证末梢神经炎的中药组合物,其特征在于:由以下重量份的各原料制成,醋北柴胡12-18份,秦艽12-18份,清半夏6-12份,党参14-26份,桂枝12-18份,炒白芍14-26份,葛根14-26份,川芎9-15份,熟地黄14-26份,当归12-18份,丹参21-39份,炙甘草7-13份。
2.根据权利要求1所述一种治疗血虚络阻证末梢神经炎的中药组合物,其特征在于:由以下重量份的各原料制成,醋北柴胡15份,秦艽15份,清半夏9份,党参20份,桂枝15份,炒白芍20份,葛根20份,川芎12份,熟地黄20份,当归15份,丹参30份,炙甘草10份。
3.根据权利要求1所述一种治疗血虚络阻证末梢神经炎的中药组合物,其特征在于:所述中药组合物剂型为汤剂、丸剂、片剂、胶囊剂、膏滋、糊剂、散剂。
4.根据权利要求3所述一种治疗血虚络阻证末梢神经炎的中药组合物,其特征在于:中药组合物的丸剂制备方法,包括以下步骤,
(1)按照重量份称取各原料药;
(2)将上述各中药原料用粉碎机粉碎成细粉,然后置于混合机中混合均匀,即得粉料;
(3)取100份上述制备得到的粉料置于混合机中,先加入淀粉和蜂蜜搅拌混合15min,再加入纯水搅拌30min,得到软材;
(4)将上述软材置于自动制丸机中拉条、搓丸,得圆整均匀、外观一致的湿丸,直径为4.0~4.3mm;
(5)将上述制备的湿丸置于微波干燥灭菌箱在55℃热风、箱内温度80℃条件下,干燥50~60分钟,得到干水分在5%以下的素丸;
(6)将上述素丸置于糖衣锅中包炭衣、滑石粉打光,得到丸剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310414806.4A CN116492412B (zh) | 2023-04-18 | 2023-04-18 | 一种治疗血虚络阻证末梢神经炎的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310414806.4A CN116492412B (zh) | 2023-04-18 | 2023-04-18 | 一种治疗血虚络阻证末梢神经炎的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116492412A CN116492412A (zh) | 2023-07-28 |
CN116492412B true CN116492412B (zh) | 2024-04-09 |
Family
ID=87317629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310414806.4A Active CN116492412B (zh) | 2023-04-18 | 2023-04-18 | 一种治疗血虚络阻证末梢神经炎的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116492412B (zh) |
-
2023
- 2023-04-18 CN CN202310414806.4A patent/CN116492412B/zh active Active
Non-Patent Citations (1)
Title |
---|
"通络祛风汤治疗末梢神经炎";王学平等;《中国现代医生》;20071130;第第45卷卷(第第20期期);第58页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116492412A (zh) | 2023-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100551422C (zh) | 一种治疗椎间盘突出的内服药物 | |
CN101810685A (zh) | 一种治疗膝关节炎症的中药组合物及其制备方法 | |
CN103705670A (zh) | 一种祛风除湿止痛的中药及其制备方法 | |
CN102366541B (zh) | 一种治疗消渴病的中药组合物 | |
CN102357177B (zh) | 一种治疗更年期综合症的中药 | |
CN102008610A (zh) | 一种治疗骨质增生的中药组合物 | |
CN103830482B (zh) | 一种治疗脑卒中的中药制剂及制备方法 | |
CN103212037B (zh) | 一种治疗女性内分泌紊乱的中药及其制备方法 | |
CN104784538A (zh) | 一种治疗糖尿病的中药制剂及制备方法 | |
CN116492412B (zh) | 一种治疗血虚络阻证末梢神经炎的中药组合物 | |
CN104547736A (zh) | 一种治疗甲状腺肿的药物 | |
CN114796325A (zh) | 一种治疗膝骨关节炎的中药组合物及其制备方法与应用 | |
CN104225221A (zh) | 一种治疗糖尿病周围性神经病变的中药 | |
CN108498772A (zh) | 用于全身调理的医用雷火灸组合物及其制备方法 | |
CN100546640C (zh) | 一种内服治疗乳腺增生的中药组合物 | |
CN111346200A (zh) | 一种用于治疗由风寒湿引起的腰腿痛病的中药制剂 | |
CN104800610A (zh) | 一种治疗帕金森病的中药制剂及其制备方法 | |
CN109646657B (zh) | 一种治疗脊神经元神经炎的中草药水煎剂 | |
CN106266548A (zh) | 治疗慢性胃炎的中药组合物、制备方法及其中药制剂 | |
CN105521391A (zh) | 一种补肝肾强筋骨的中药及其制备方法 | |
CN104042908A (zh) | 一种治疗妇女更年期综合症的中药组合物 | |
CN104922595A (zh) | 一种用于带状疱疹的中药制剂及其制备方法 | |
CN104436060A (zh) | 一种护理治疗胆管细胞癌的中药配方及其制备方法 | |
CN114129697A (zh) | 一种升阳汤及其制备方法 | |
CN104116940A (zh) | 一种治疗妇女更年期综合症的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |